收入和利润 - 2024年净亏损为2060万美元，较2023年的720万美元增加1340万美元[10][13] 成本和费用 - 2024年研发费用为1740万美元，较2023年的450万美元增加1290万美元[10][13] - 2024年一般及行政费用为530万美元，较2023年的220万美元增加310万美元[10][13] - 2024年总运营费用为2279万美元，较2023年的742万美元大幅增加[13] 业务线表现 - ARD-101在PWS二期试验中显示高食症评分平均降低约8分[5] - ARD-101治疗28天后体脂减少约1.5%，瘦肌肉增加超过2%[5] - 三期HERO试验顶线数据预计2026年初公布[5][10] 资金和投资 - 截至2024年12月31日，公司现金、现金等价物和短期投资为7370万美元[10] - 2025年2月IPO成功募集资金9790万美元[5][6] - 公司现有资金预计可支持运营至2027年[10]

Table of Contents As filed with the Securities and Exchange Commission on February 6, 2025 Registration No. 333-284440 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT Under The Securities Act Of 1933 AARDVARK THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 82-1606367 (Primary Standard Industrial Classification Code Number) (I.R.S. E ...

Table of Contents As filed with the Securities and Exchange Commission on January 23, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act Of 1933 AARDVARK THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 4370 La Jolla Village Drive, Suite 1050 San Diego, CA 92122 (858) 225-7696 (Address, including zip code, and telepho ...